NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Syros Pharmaceuticals Inc (NASDAQ:SYRS) released its earnings results on Tuesday, November, 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.01. The firm had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.43 million. Syros Pharmaceuticals had a negative return on equity of 84.49% and a negative net margin of 3,115.38%. View Syros Pharmaceuticals' Earnings History.

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals.

7 Wall Street analysts have issued 12 month price targets for Syros Pharmaceuticals' shares. Their forecasts range from $9.00 to $18.00. On average, they anticipate Syros Pharmaceuticals' stock price to reach $13.83 in the next twelve months. This suggests a possible upside of 88.2% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.

News articles about SYRS stock have trended somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a news sentiment score of -1.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Syros Pharmaceuticals.

Syros Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,490,000 shares, an increase of 6.4% from the January 15th total of 2,340,000 shares. Based on an average trading volume of 458,600 shares, the days-to-cover ratio is presently 5.4 days. Approximately 8.1% of the shares of the stock are short sold. View Syros Pharmaceuticals' Current Options Chain.

Some companies that are related to Syros Pharmaceuticals include Akebia Therapeutics (AKBA), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Odonate Therapeutics (ODT), NextCure (NXTC), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Phathom Pharmaceuticals (PHAT), Portola Pharmaceuticals (PTLA), Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA), Dermira (DERM), Myovant Sciences (MYOV) and I-Mab (ARQT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), ImmunoGen (IMGN), Zynerba Pharmaceuticals (ZYNE), Abeona Therapeutics (ABEO), Amarin (AMRN), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR) and Vanda Pharmaceuticals (VNDA).

(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Syros Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.96%), Nikko Asset Management Americas Inc. (11.72%), Sumitomo Mitsui Trust Holdings Inc. (11.72%), Arch Venture Corp (7.81%), State Street Corp (1.61%) and Geode Capital Management LLC (1.12%). Company insiders that own Syros Pharmaceuticals stock include Jeremy P Springhorn, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View Institutional Ownership Trends for Syros Pharmaceuticals.

SYRS stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Renaissance Technologies LLC, New York State Common Retirement Fund and ProShare Advisors LLC. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Richard A Young and Venture Fund Vii LP Arch. View Insider Buying and Selling for Syros Pharmaceuticals.

SYRS stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Jacobs Levy Equity Management Inc., Algert Global LLC, California Public Employees Retirement System, Acadian Asset Management LLC and Geode Capital Management LLC. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYRS stock can currently be purchased for approximately $7.35.

Syros Pharmaceuticals has a market capitalization of $311.93 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.

The official website for Syros Pharmaceuticals is http://www.syros.com/.

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]